Physician profile
Basem Hamid
NPI 1114918265
$2,855.82
in general payments reported to CMS, 2019-2025
25 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,614 · 2020: $65.69 · 2021: $119 · 2022: $248 · 2023: $301 · 2024: $239 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $1,505.97 | 2019 | |
| Abbvie INC. | $359.12 | 2022-2025 | |
| Pfizer INC. | $207.13 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.81 | 2019-2023 | Relistor |
| Collegium Pharmaceutical, INC. | $103.12 | 2019-2024 | Xtampza, Belbuca |
| Amgen INC. | $88.55 | 2019-2021 | |
| Spr Therapeutics, INC | $49.64 | 2025 | Sprint Pns System |
| Biohaven Pharmaceuticals, INC. | $45.68 | 2021 | |
| Scilex Pharmaceuticals INC. | $36.04 | 2021-2022 | |
| Axsome Therapeutics, INC. | $32.40 | 2025 | Symbravo |
| Biohaven Pharmaceutical Holding Company LTD. | $31.06 | 2022 | |
| Fidia Pharma USA INC. | $28.32 | 2024 | Hymovis |
| Nevro Corp. | $25.95 | 2020 | |
| Zyla Life Sciences, INC. | $24.77 | 2019 | |
| Boston Scientific Corporation | $24.21 | 2025 | Intracept |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $23.90 | 2025 | Vyepti |
| Pacira Therapeutics, INC. | $17.66 | 2019 | |
| Lilly USA, LLC | $16.20 | 2022 | |
| Assertio Therapeutics, INC. | $15.12 | 2020 | |
| Valinor Pharma, LLC | $14.88 | 2025 | Movantik |
| Kowa Pharmaceuticals America, INC. | $13.92 | 2023 | Seglentis |
| Relievant Medsystems, INC. | $13.68 | 2022 | |
| Biodelivery Sciences International, INC. | $13.52 | 2021 | |
| Depuy Synthes Sales INC. | $13.37 | 2024 | Orthovisc, Monovisc |
| Arbor Pharmaceuticals, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basem Hamid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.